

Chemicals

Some respite in pricing pressures

Summary

The consistent fall in chemical prices was arrested to some extent in July. Most of the management commentaries do point to slow global demand offtake and significant channel destocking especially in the agrochemical segment. China has been aggressively entering various segments and impacting them by steep pricing and volume dumping. We expect pricing pressures to sustain for commodity chemicals with Chinese resurgence. However, realignment in the global supply chain to diversify from China and strong interest from global MNCs to source from India bode favourably for the Indian chemical sector. Companies with long term contracts which have price variation clauses embedded in them will fare better owing to better revenue visibility and margin protection. Companies who are higher up the specialty chemicals value chain stand to perform better in the current environment.

Key Highlights

- Pricing Pressures remain: We chart out price data for various chemicals further in this report and present select highlights here. Mono Ethylene Glycol (MEG) prices increased by 9% MoM. MEG is more commonly used as a polymer precursor and as an antifreeze application. India Glycol is a major manufacturer of MEG domestically. Caustic Soda Lye prices have declined by 9% MoM as the industry is facing challenges in terms of weak demand and slow sales leading to higher inventory levels. Acetic acid prices have risen by 12% MoM. It forms a key input for manufacturing ethyl acetate and acetic anhydride. Soda ash (Dense) prices have risen by 2% MoM to Rs 41/kg. Toluene and Acetone prices are up by 20% and 12% MoM respectively.
- Outlook: We believe that commodity chemicals segment would be under pressure especially in the wake of increasing competition from China. We prefer specialty chemical players with decades of rich experience, deep chemistry prowess and strong R&D and execution capabilities. Companies that are delivering value added products and moving up the value chain will fare better as compared to pure commodity plays.

Pricing Snapshot

Chemical	Jul-23	Jul-23 Jul-22		Jun-23	MoM (Chg)
Benzene	82	114	-28%	85	-4%
Aniline	170	189	-10%	161	6%
Heavy Soda Ash	41	50	-18%	40	2%
Toluene	106	102	4%	89	20%
Phthalic Anhydride	98	107	-8%	105	-7%
Monoethylene Glycol (MEG)	62	66	-6%	57	9%
Phenol	114	148	-23%	100	14%
Acetone	84	76	11%	75	12%
Isopropyl Alcohol (IPA)	103	106	-3%	97	6%
Acetonitrile	131	170	-23%	126	4%
Acetic Acid	57	66	-14%	51	12%
Caustic Soda Lye	29	51	-43%	32	-9%
Ethyl Acetate	89	95	-6%	83	7%
Toluene Diisocyanate (TDI)	196	247	-21%	204	-3.9%
Maleic Anhydride	85	136	-38%	88	-3%
Methanol	31	35	-13%	30	2%
Phthalic Anhydride	98	107	-8%	105	-7%
Acrylic Acid	97	180	-46%	93	4%
LDPE	103	134	-23%	102	1%
HDPE	107	126	-15%	106	1%

Source: Indianpetrochem, Change % based on month end prices

Jason Soans

Jason.soans@idbicapital.com +91-22-2217 1727



Exhibit 1: Brief Profile

Chemicals	Indian Manufacturer	Major Consumer		
Benzene	BPCL, RIL, IOCL, ONGC	Aarti Inds, Apcotex, CFS, NFIL, Vinati, Deepak Nitrite, Valiant Org, Jyothy Labs		
Aniline	GNFC, HOCL	Aarti Ind, Atul Ltd, Aurobindo, Bayer, Monsanto, UPL, BA Deepak Nitrite, Nocil, Valiant Org, Bodal, Bhageria, Kiri		
Soda Ash	Tata Chem, GHCL, DCW, GFL	Deepak Nitrite		
Toluene	Reliance, BPCL, Indian Oil	Aarti, NFIL, Vinati, Deepak Nitrite		
Phthalic Anhydride	Thirumalai Chem, IGPL			
Mono Ethylene Glycol	RIL, India Glycols, IOCL			
Phenol	Deepak Phenolics, SI Group			
Acetone	Deepak Phenolics, SI Group	GSFC, ITC, Berger, Shalimar, Torrent Pharma, Sun Pharma, Asian Paints, Kansai Nerolac, Pfizer, NFIL		
Iso Propyl Alcohol (IPA)	Deepak Nitrite			
Acetonitrile	Alkyl amines, Balaji amines, Deepak Novochem			
Acetic acid	Jubilant Ingrevia, GNFC	Reliance, IOCL, Apcotex, SRF, Deepak Nitrite, Laxmi Org.		
Caustic soda	Grasim, DCM Shriram, GACL, Nalco, RIL, DCW, TGV Sraac	Arvind Mills, Deepak Nitrite, GNFC, GSFC, IOC, Meghmani Organics, Nirma, NALCO, HUL, UPL		
Ethyl Acetate	GNFC, Jubilant Ingrevia, Laxmi Organics			
TDI	BASF, GNFC			
High-Density Polyethylene (HDPE)	Reliance, ONGC, GAIL			
Low-Density Polyethylene (LDPE)	Reliance			
Maleic Anhydride	Thirumalai Chem, IGPL			
Methanol	RCF, NFL, IOCL, Deepak Fertilizers, GNFC, GSFC	Alkyl Amines, Balaji Amines, Aarti, CFS, NFIL, SRF, Vinati		
PAN (Phthalic Anhydride)	Thirumalai Chem, IGPL			
Acrylic Acid	BPCL, IOCL, BASF, GSFC	Apcotex, Black Rose, Balmer Lawrie, Fineotex		

Source: Company; IDBI Capital Research



Exhibit 2: Benzene Prices down by ~4% MoM




Exhibit 3: Aniline Prices up by ~6% MoM



Source: Indianpetrochem

Exhibit 4: Heavy Soda Ash Prices up by ~2% MoM



Source: Indianpetrochem

Exhibit 5: Toluene Prices up by ~20% MoM






Exhibit 6: Phthalic Anhydride Prices down by ~7% MoM



Exhibit 7: Monoethylene Glycol Prices up by ~9% MoM



Source: Indianpetrochem

Exhibit 8: Phenol Prices up by ~14% MoM





Exhibit 9: Acetone Prices up by ~12% MoM












Exhibit 11: Acetonitrile Prices up by ~4% MoM



Source: Indianpetrochem

Source: Indianpetrochem

Exhibit 12: Acetic Acid Prices up by ~12% MoM



Source: Indianpetrochem

Exhibit 13: Caustic Soda Prices down by ~9% MoM






Exhibit 14: Ethyl Acetate Prices up by ~7% MoM






Exhibit 15: Toluene Diisocyanate Prices down by ~4% MoM



Source: Indianpetrochem

Exhibit 16: Maleic Anhydride down by ~3% MoM



Source: Indianpetrochem

Exhibit 17: HDPE up by ~1% MoM









Exhibit 19: Methanol up by ~2% MoM



Source: Indianpetrochem

Exhibit 20: Acrylic Acid up by ~4% MoM



Source: Indianpetrochem

Exhibit 21: Phthalic Anhydride down by ~7% MoM






Exhibit 22: Sectoral Stock Performance

	Mkt Cap	Mkt Cap			Performance (%)			Relative to Index (%)		
	Rs bn	1M	12M	3 Year	5 Year	1M	12M	3 Year	5 Year	
SRF	672	-5	-11	184	528	-8	-26	106	453	
Gujarat Fluorochemicals	308	-7	-19	530	-	-10	-34	452	-	
Deepak Nitrite	278	-8	5	214	731	-10	-10	136	657	
Navin Fluorine International	223	-5	-3	133	544	-8	-18	55	470	
Aarti Industries	171	-7	-31	5	75	-10	-46	-73	1	
Fine Organics	141	-8	-16	93	461	-11	-31	15	387	
Aether Industries	138	-3	-	-	-	-6	-	-	-	
Alkyl Amines	124	-10	-16	147	835	-13	-32	69	761	
Anupam Rasayan	100	-5	22	-	-	-8	7	-	-	
Galaxy Surfactants	93	3	-12	63	124	0	-27	-15	50	
GNFC	91	-1	-18	261	42	-4	-33	183	-32	
Balaji Amines	72	-6	-36	263	278	-8	-51	185	204	
Laxmi Organics	71	4	-13	-	-	1	-28	-	-	
Jubilant Ingrevia	68	-3	-22	-	-	-6	-37	-	-	
Gujarat Alkalies and Chemicals	52	3	-15	283	120	0	-30	205	46	
GHCL	50	-3	-12	97	19	-6	-28	19	-55	
Ami Organics	45	-10	10	-	-	-13	-5	-	-	
Neogen Chemicals	39	-1	17	154	-	-4	2	76	-	
I G Petrochemicals	14	-16	-32	153	-7	-19	-47	75	-82	

Source: Bloomberg, IDBI Capital Research





Dealing (91-22) 6836 1111 dealing@idbicapital.com

Key to Ratings Stocks:

BUY: 15%+; **HOLD:** -5% to 15%; **SELL:** -5% and below.

IDBI Capital Markets & Securities Ltd.

Equity Research Desk

6th Floor, IDBI Tower, WTC Complex, Cuffe Parade, Colaba, Mumbai – 400 005. Phones: (91-22) 2217 1700; Fax: (91-22) 2215 1787; Email: info@idbicapital.com

SEBI Registration: BSE & NSE (Cash & FO) - INZ000007237, NSDL - IN-DP-NSDL-12-96, Research - INH000002459, CIN - U65990MH1993GOI075578

Compliance Officer: Christina D'souza; Email: compliance@idbicapital.com; Telephone: (91-22) 2217 1907

Disclaimer

This report has been published by IDBI Capital Markets & Securities Ltd.(hereinafter referred to as "IDBI Capital") for private circulation. This report should not be reproduced or copied or made available to others. No person associated with IDBI Capital is obligated to call or initiate contact with you for the purposes of elaborating or following up on the information contained in this report. The information contained herein is strictly confidential and meant for solely for the selected recipient and may not be altered in any way, transmitted to copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without the prior written consent of IDBI Capital.

Recipients may not receive this report at the same time as other recipients. IDBI Capital will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is from the public domain or sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be reliable upon as such. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be reliable upon as such. In so far as this report includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Opinions expressed are current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis, the information discussed in this material, IDBI Capital, its directors, employees are under no obligation to update or keep the information current. Further there may be regulatory, compliance, or other reasons that prevent us from doing so.

Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.

IDBI Capital, its directors and employees and any person connected with it, will not in any way be responsible for the contents of this report or for any losses, costs, expenses, charges, including notional losses/lost opportunities incurred by a recipient as a result of acting or non-acting on any information/material contained in the report.

This is not an offer to sell or a solicitation to buy any securities or an attempt to influence the opinion or behavior of investors or recipients or provide any investment/tax advice.

This report is for information only and has not been prepared based on specific investment objectives. The securities discussed in this report may not be suitable for all investors. Investors must make their own investment decision based on their own investment objectives, goals and financial position and based on their own analysis.

Trading in stocks, stock derivatives, and other securities is inherently risky and the recipient agrees to assume complete and full responsibility for the outcomes of all trading decisions that the recipient makes, including but not limited to loss of capital.

Opinions, projections and estimates in this report solely constitute the current judgment of the author of this report as of the date of this report and do not in any way reflect the views of IDBI Capital, its directors, officers, or employees.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IDBI Capital and associates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this report may come are required to inform themselves of and to observe such restriction.

E-mail is not a secure method of communication. IDBI Capital cannot accept responsibility for the accuracy or completeness of any e-mail message or any attachment(s).

This transmission could contain viruses, be corrupted, destroyed, incomplete, intercepted, lost or arrived late. IDBI Capital, its directors or employees or associates accept no liability for any damage caused, directly or indirectly, by this email.

Chemicals | Monthly Pricing Update



Analyst Disclosures

I, Jason Soans, hereby certify that the views expressed in this report accurately reflect my personal views about the subject companies and / or securities. I also certify that no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report. Principally, I will be responsible for the preparation of this research report and have taken reasonable care to achieve and maintain independence and objectivity in making any recommendations herein.

Other Disclosure

IDBI Capital Markets & Securities Ltd. (herein after referred to as "IDBI Capital") was incorporated in the year 1993 under Companies Act, 1956 and is a wholly owned subsidiary of IDBI Bank Limited. IDBI Capital is one of India's leading securities firm which offers a full suite of products and services to individual, institutional and corporate clients namely Stock broking (Institutional and Retail), Distribution of financial products, Merchant Banking, Corporate Advisory Services, Debt Arranging & Underwriting, Portfolio Manager Services and providing Depository Services. IDBI Capital is a registered trading and clearing member of BSE Ltd. (BSE) and National Stock Exchange of India Limited (NSE). IDBI Capital is also a SEBI registered Merchant Banker, Portfolio Manager and Research Analyst. IDBI Capital is also a SEBI registered depository participant with National Securities Depository Limited (NSDL) and is also a Mutual Fund Advisor registered with Association of Mutual Funds in India (AMFI).

IDBI Capital and its associates IDBI Bank Ltd. (Holding Company), IDBI Intech Ltd. (Fellow Subsidiary), IDBI Asset Management Ltd. (Fellow Subsidiary) and IDBI Trusteeship Services Ltd. (Fellow Subsidiary).

IDBI Group is a full-serviced banking, integrated investment banking, investment management, brokerage and financing group. Details in respect of which are available on www.idbicapital.com IDBI Capital along with its associates are leading underwriter of securities and participants in virtually all securities trading markets in India. We and our associates have investment banking and other business relationships with a significant percentage of the companies covered by our Research Department. Investors should assume that IDBI Capital and/or its associates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material. IDBI Capital generally prohibits its analysts, persons reporting to analysts, and their dependent family members having a financial conflict of interest in the securities or derivatives of any companies that the analysts cover. Additionally, IDBI Capital generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Directors of IDBI Capital and its associates may have interest in the Companies under recommendation in this report either as Director or shareholder. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This material should not be construed as an offer to sell or the solicitation of an offer to buy a

IDBI Capital hereby declares that our activities were neither suspended nor we have materially defaulted with any Stock Exchange authority with whom we are registered in last five years. However SEBI, Exchanges and Depositories have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on IDBI Capital for certain operational deviations. We have not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has our certificate of registration been cancelled by SEBI at any point of time. IDBI Capital, its directors or employees or associates, may from time to time, have positions in, or options on, and buy and sell securities referred to herein. IDBI Capital or its associates may notice that in the financial instruments of the company(ies) discussed herein or their affiliate company mentioned in this document or their connected persons or be engaged in any other transaction involving such securities and earn brokerage or other compensation or at as a market maker in the financial instruments of the company(ies) discussed herein or their affiliate companies or act as advisor or lender / borrower to such company(ies)/associates companies or have other potential conflict of interest. This report may provide hyperlinks to other websites. Except to the extent to which the report refers to the website of IDBI Capital, IDBI Capital states that it has not reviewed the linked site and takes no responsibility for the content contained in such other websites. Accessing such websites shall be at recipient's own risk. IDBI Capital on file report. Accordingly, neither IDBI Capital nor Research Analysts have any material conflict of interest at the time of publication of this report. We offer our research services to primarily institutional investors and their employees, directors, fund managers, advisors who are registered with us. The Research Analyst has not served as an officer, director or employee of Subject Company. We or our